IRESSA (gefitinib) for Metastatic EGFR Mutation-Positive NSCLC - Cancer Therapy Advisor

IRESSA (gefitinib) for Metastatic EGFR Mutation-Positive NSCLC

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow reviews drug information for IRESSA (gefitinib), indicated for metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC).

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 8: Use in Specific Populations
Slide 10: Clinical Pharmacology
Slide 15: Warnings and Precautions
Slide 20: Clinical Safety and Efficacy
Slide 25: Drug Storage and Supply
Slide 27: References

Next hm-slideshow in Slides